Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Systemic Sclerosis (Scleroderma)-Pipeline Review, H1 2015

Systemic Sclerosis (Scleroderma)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Systemic Sclerosis (Scleroderma)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Systemic Sclerosis (Scleroderma)-Pipeline Review, H1 2015', provides an overview of the Systemic Sclerosis (Scleroderma)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Systemic Sclerosis (Scleroderma) Overview 10

Therapeutics Development 11

Pipeline Products for Systemic Sclerosis (Scleroderma)-Overview 11

Pipeline Products for Systemic Sclerosis (Scleroderma)-Comparative Analysis 12

Systemic Sclerosis (Scleroderma)-Therapeutics under Development by Companies 13

Systemic Sclerosis (Scleroderma)-Therapeutics under Investigation by Universities/Institutes 16

Systemic Sclerosis (Scleroderma)-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Systemic Sclerosis (Scleroderma)-Products under Development by Companies 20

Systemic Sclerosis (Scleroderma)-Products under Investigation by Universities/Institutes 22

Systemic Sclerosis (Scleroderma)-Companies Involved in Therapeutics Development 23

Active Biotech AB 23

Allergan, Inc. 24

Angion Biomedica Corp. 25

arGentis Pharmaceuticals, LLC 26

Auspex Pharmaceuticals, Inc. 27

Bayer AG 28

BioLineRx, Ltd. 29

Bristol-Myers Squibb Company 30

Celgene Corporation 31

Corbus pharmaceuticals, Inc. 32

Daval International Ltd. 33

Digna Biotech, S.L. 34

Dynavax Technologies Corporation 35

F. Hoffmann-La Roche Ltd. 36

Fibrocell Science, Inc. 37

GlaxoSmithKline plc 38

iBio, Inc. 39

Inventiva SAS 40

MedImmune, LLC 41

NovaLead Pharma Pvt. Ltd. 42

Vida Therapeutics Inc. 43

VivaCell Biotechnology Espana S.L. 44

Systemic Sclerosis (Scleroderma)-Therapeutics Assessment 45

Assessment by Monotherapy Products 45

Assessment by Target 46

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

abatacept (recombinant)-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

acALY-18-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Aimspro-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

ANG-3070-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ARG-201-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

belimumab-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

BL-1110-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

CC-220-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

disitertide-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

DV-1179-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

GMHDFCOL-7-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

IBIOCFB-03-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

IVA-337-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

JBT-101-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

MEDI-551-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

NLP-491-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Oligonucleotide for Scleroderma-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

onabotulinumtoxin A-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

P-17-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

paquinimod-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

PAT-048-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

pomalidomide-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

riociguat-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SD-560-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Small Molecule to Inhibit NFkB for Immunology and Oncology-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Stem Cell Therapy for Crohns Disease and Systemic Sclerosis-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

tocilizumab-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

V-2248-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

VCE-0048-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

VEDA-1209-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Systemic Sclerosis (Scleroderma)-Recent Pipeline Updates 102

Systemic Sclerosis (Scleroderma)-Dormant Projects 129

Systemic Sclerosis (Scleroderma)-Discontinued Products 131

Systemic Sclerosis (Scleroderma)-Product Development Milestones 132

Featured News & Press Releases 132

Jan 07, 2015: Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences 132

Dec 10, 2014: iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting 132

Dec 08, 2014: Cureveda Awarded Two NIH Small Business Grants to Develop Treatments for Systemic Sclerosis and COPD 134

Dec 03, 2014: Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014 134

Nov 03, 2014: Inventiva receives positive opinion on orphan drug designation in the European Union for IVA337-a treatment for Systemic Sclerosis (SSc) 135

Oct 22, 2014: iBio Expands Exclusive Product Collaboration With Novici Biotech 135

Oct 01, 2014: Corbus Pharmaceuticals to Present at the 13th Annual BIO Investor Forum in San Francisco on Wednesday, October 8, 2014 136

Sep 30, 2014: Corbus Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable in New York on Wednesday, October 1, 2014 136

Jun 11, 2014: Active Biotech Presents Data On Paquinimod At Eular 2014 136

Feb 25, 2014: Daval International Announces the Granting of Orphan Drug Designation by the FDA for AIMSPRO 137

Appendix 138

Methodology 138

Coverage 138

Secondary Research 138

Primary Research 138

Expert Panel Validation 138

Contact Us 138

Disclaimer 139

List of Tables

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2015 11

Number of Products under Development for Systemic Sclerosis (Scleroderma)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Systemic Sclerosis (Scleroderma)-Pipeline by Active Biotech AB, H1 2015 23

Systemic Sclerosis (Scleroderma)-Pipeline by Allergan, Inc., H1 2015 24

Systemic Sclerosis (Scleroderma)-Pipeline by Angion Biomedica Corp., H1 2015 25

Systemic Sclerosis (Scleroderma)-Pipeline by arGentis Pharmaceuticals, LLC, H1 2015 26

Systemic Sclerosis (Scleroderma)-Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 27

Systemic Sclerosis (Scleroderma)-Pipeline by Bayer AG, H1 2015 28

Systemic Sclerosis (Scleroderma)-Pipeline by BioLineRx, Ltd., H1 2015 29

Systemic Sclerosis (Scleroderma)-Pipeline by Bristol-Myers Squibb Company, H1 2015 30

Systemic Sclerosis (Scleroderma)-Pipeline by Celgene Corporation, H1 2015 31

Systemic Sclerosis (Scleroderma)-Pipeline by Corbus pharmaceuticals, Inc., H1 2015 32

Systemic Sclerosis (Scleroderma)-Pipeline by Daval International Ltd., H1 2015 33

Systemic Sclerosis (Scleroderma)-Pipeline by Digna Biotech, S.L., H1 2015 34

Systemic Sclerosis (Scleroderma)-Pipeline by Dynavax Technologies Corporation, H1 2015 35

Systemic Sclerosis (Scleroderma)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 36

Systemic Sclerosis (Scleroderma)-Pipeline by Fibrocell Science, Inc., H1 2015 37

Systemic Sclerosis (Scleroderma)-Pipeline by GlaxoSmithKline plc, H1 2015 38

Systemic Sclerosis (Scleroderma)-Pipeline by iBio, Inc., H1 2015 39

Systemic Sclerosis (Scleroderma)-Pipeline by Inventiva SAS, H1 2015 40

Systemic Sclerosis (Scleroderma)-Pipeline by MedImmune, LLC, H1 2015 41

Systemic Sclerosis (Scleroderma)-Pipeline by NovaLead Pharma Pvt. Ltd., H1 2015 42

Systemic Sclerosis (Scleroderma)-Pipeline by Vida Therapeutics Inc., H1 2015 43

Systemic Sclerosis (Scleroderma)-Pipeline by VivaCell Biotechnology Espana S.L., H1 2015 44

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Stage and Target, H1 2015 47

Number of Products by Stage and Mechanism of Action, H1 2015 49

Number of Products by Stage and Route of Administration, H1 2015 51

Number of Products by Stage and Molecule Type, H1 2015 53

Systemic Sclerosis (Scleroderma) Therapeutics-Recent Pipeline Updates, H1 2015 102

Systemic Sclerosis (Scleroderma)-Dormant Projects, H1 2015 129

Systemic Sclerosis (Scleroderma)-Dormant Projects (Contd..1), H1 2015 130

Systemic Sclerosis (Scleroderma)-Discontinued Products, H1 2015 131

List of Figures

Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2015 11

Number of Products under Development for Systemic Sclerosis (Scleroderma)-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 45

Number of Products by Top 10 Targets, H1 2015 46

Number of Products by Stage and Top 10 Targets, H1 2015 46

Number of Products by Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Top 10 Routes of Administration, H1 2015 50

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 50

Number of Products by Top 10 Molecule Types, H1 2015 52

Number of Products by Stage and Top 10 Molecule Types, H1 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Active Biotech AB

Allergan, Inc.

Angion Biomedica Corp.

arGentis Pharmaceuticals, LLC

Auspex Pharmaceuticals, Inc.

Bayer AG

BioLineRx, Ltd.

Bristol-Myers Squibb Company

Celgene Corporation

Corbus pharmaceuticals, Inc.

Daval International Ltd.

Digna Biotech, S.L.

Dynavax Technologies Corporation

F. Hoffmann-La Roche Ltd.

Fibrocell Science, Inc.

GlaxoSmithKline plc

iBio, Inc.

Inventiva SAS

MedImmune, LLC

NovaLead Pharma Pvt. Ltd.

Vida Therapeutics Inc.

VivaCell Biotechnology Espana S.L.

Systemic Sclerosis (Scleroderma) Therapeutic Products under Development, Key Players in Systemic Sclerosis (Scleroderma) Therapeutics, Systemic Sclerosis (Scleroderma) Pipeline Overview, Systemic Sclerosis (Scleroderma) Pipeline, Systemic Sclerosis (Scleroderma) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com